As the medtech sector expands in Europe, companies must carefully assess their real estate strategies—whether to lease or own—against a backdrop of innovation, regulation, and rapid product development. Like pharma and CDMO/CRO peers, medtech companies require specialised buildings, often in cluster regions, but their real estate decisions are shaped by distinct product lifecycles, firm sizes, and operating models.
Investment
Medtech companies and their real estate
European medtech companies navigate complex real estate decisions across innovation clusters, balancing flexibility needs with regulatory requirements.
5 min read
More from Life Sciences Real Estate
paid
Niche sector, strong momentum: life sciences' growing share of the UK commercial property market
Life sciences real estate is a specialised segment expanding at a speed that outpaces most traditional property sectors.
4 min read
paid
How CROs and CDMOs navigate real estate decisions
Life science contract organisations balance real estate ownership (73 per cent) vs leasing (27 per cent) based on financial, operational, and strategic considerations.
5 min read
paid
Is Life Science REIT nearing its end?
LABS is exploring options including potential sale or wind-down after facing market challenges, with shares trading at a steep discount to NAV.
3 min read